Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Feb 20, 2013 6:45 PM Flag

    NCCN 18th Annual Conference update

    $$$$

    Just added! Lunch Symposium
    "Management of Castration-Resistant Prostate Cancer: Envisioning a Chronic Disease Paradigm"
    Friday, March 15, 2013

    Dunno if such an affair might eventually be made available on video...
    But I figure it'll be worth looking for...This lunch symposium was added just 3 weeks before the conference is to meet, and added to an already fully planned agenda.
    I figure somebody important has got something important to say...
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • this does not mean cabo will be mentioned or does it?

      • 1 Reply to marinolman11
      • $$$$

        "this does not mean cabo will be mentioned or does it?"

        Unknown. But, Dr Philip Kantoff has published in the JNCCN as recently as last November with reference to Cabozantinib - you can verify that just by reading the abstract. Since that November issue of the JNCCN, the P2 RDT CRPC results have published in the JCO - an important, peer-reviewed publication.. With so many recent approvals in CRPC treatment, the discussion will undoubedly cover the gamut of the treatment algoritm. If the topic of advanced-stage CRPC bone mets management is broached, such clinical crosstalk would seem incomplete without reference to those recently published JCO P2 Cabo results - JMHO

 
EXEL
3.11+0.01(+0.32%)Apr 17 4:00 PMEDT